Telix Pharmaceuticals (TLX) H2 2024 earnings summary

Executive summary

• Achieved record revenue of AU$783.2 million in FY2024, a 56% year-over-year increase, primarily from Illuccix sales and strategic acquisitions, transforming into a diversified, multinational company.

• Delivered second consecutive year of profitable growth, with profit after tax up 860% to AU$49.9 million, and invested heavily in late-stage pipeline, manufacturing, and global expansion, including a Nasdaq listing.

• Positioned as a multi-product, global commercial company with multiple therapeutic assets in pivotal trials and expanded infrastructure.

• Preparing to launch three new products in the U.S. in 2025 and expand Illuccix into Europe and the U.K., with a robust late-stage therapeutic pipeline in prostate, kidney, and brain cancer.

Financial highlights

• Revenue increased 56% year-over-year to AU$783.2M; adjusted EBITDA rose 70% to AU$99.3M; operating cash inflow improved 80% to AU$43.0M.

• Profit after tax surged 860% to AU$49.9M; operating profit up 423% to AU$82.1M.

• Gross margin improved to 65% (from 63% in 2023); gross profit rose 62% to AU$509.6M.

• Ended 2024 with AU$710.3M in cash, bolstered by AU$635M–AU$650M convertible bond placement.

• One-off costs related to U.S. IPO, acquisitions, and FX gains/losses excluded from adjusted EBITDA.

Outlook and guidance

• FY2025 revenue guidance set at AU$1.18B–AU$1.23B, driven by Illuccix sales and 11 months of RLS revenue, excluding new product launches pending regulatory approval.

• R&D investment expected to increase by 20%–25% over 2024, supporting late-stage and next-generation pipeline.

• Anticipates launching three new products in the U.S. and expanding into 19 European countries, with further regulatory progress in China and Japan.

• Expects a step change in profitability and cash generation from 2027 as therapeutic products reach commercialization.

• Guidance excludes revenue from products pending regulatory approval.